Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of cetuximab with rapidly alternating chemoradiation in unresectable locally advanced head and neck cancer
2004-000411-25Phase 2Active
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Sep 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Started Sep 2005; status: active.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2004-000411-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000411-25.